Ceram and AstraZeneca in controlled release study

AstraZeneca has signed an agreement with Ceram Research that will see Ceram develop its inorganic-based controlled release technology in a feasibility study for the delivery of selected AstraZeneca compounds.

According to Tony Kinsella, chief executive officer at Ceram, if the technology is successfully implemented, it could provide AstraZeneca with an alternative formulation approach for delivering the compounds.

Ceram’s materials experts are also working on multi-element substituted hydroxyapatite for orthopaedic device coating applications.